A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma
A Phase IB, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of Vemurafenib in Combination With GDC-0973 (Cobimetinib) When Administered in BRAFV600E Mutation-Positive Patients Previously Treated (But Without Prior Exposure to BRAF or MEK Inhibitor Therapy) or Previously Untreated for Locally Advanced/Unresectable or Metastatic Melanoma or Those Who Have Progressed After Treatment With Vemurafenib
Sponsor: Hoffmann-La Roche
A PHASE1 clinical study on Malignant Melanoma, this trial is completed. The trial is conducted by Hoffmann-La Roche and has accumulated 10 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Dec 2018 — Aug 2019 [monthly]
Completed PHASE1
▶ Show 5 earlier versions
-
Jul 2018 — Dec 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE1
-
Jun 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Feb 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .